Key clinical point: A fixed-duration venetoclax-obinutuzumab regimen is safe and provides a superior outcome versus standard chlorambucil plus obinutuzumab in elderly patients with chronic lymphocytic leukemia (CLL) and comorbidities.
Major finding: At 24 months, progression-free survival was 88.2% for the venetoclax-obinutuzumab regimen, versus 64.1% for chlorambucil-obinutuzumab (hazard ratio, 0.35; 95% confidence interval, 0.23-0.53; P less than .0001).
Study details: Results of CLL-14, a randomized phase 3 trial including 432 patients with untreated CLL and comorbidities.
Disclosures: F. Hoffmann-La Roche and AbbVie supported the study. Dr. Fischer reported travel, accommodations, or expenses from Roche in her abstract disclosure.
Fischer K et al. ASCO 2019, Abstract 7502.